May 2009

Saturday, May 9, 2009

I Have Had A Stroke Card

CEUTA EYES: Encapsulated Cell Technology (ECT) FOR DRY MACULAR DEGENERATION EYE OPHTHALMOLOGY

* *

* *
*

http://www.neurotechusa.com/ect/about_encapsulated_cell_technology.asp

Encapsulated Cell Technology (ECT), developed by the company Neurotech (Rhode Island) has managed to keep the vision in the vast majority of patients who participated in Phase II clinical trial conducted for the treatment of degeneration Macular Seca.
*
So far there is no effective treatment for dry AMD, a leading cause of blindness in people over 55 in developed countries.
*
The 96.3% of patients receiving high dose treatment have maintained stable vision after a follow up of 12 months, although it is the patients with better acuity initial visual (2 / 3 or more) that have benefited most.
*
Patients with stable vision have also developed a thickening of their retinas, which seems aumeto translate a density of photoreceptors. * ECT
The implant is a small device (about the size of a grain of rice) contains cells capable of providing consistently and continuously called ciliary neurotrophic factor protein involved in stabilizing macular.
*
Preclinical studies have been funded by the Foundation Fighting Blindness, like esudios maintains phase II / III for treatment of retinitis pigmentosa, Usher syndrome and coroidemia.
*
The results of these trials will be announced at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) meeting in the month of May in Fort Lauderdale (Florida).
*
View previous post:

http://ojosdeceuta.blogspot.com/2007/01/estado-del-tratamiento-de-la.html
*
Basic Information and Guidance. For a custom Info consult your ophthalmologist.
*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Saturday, May 2, 2009

Appraisal Districts In Scottsdale In Arizona

CEUTA: STEM CELL TRANSPLANT FOR AMD. EYE OPHTHALMOLOGY

+ +

We get questions about the story recently published in many media on Degeneration Treatment MACULAR STEM CELLS.

British scientists from University College London (UCL) have developed a treatment study (clinical trial) for Macular Degeneration (AMD) - from the use of stem cells, which could begin to implement by 2015.

*
The study of treatment is to replace the layer of eye cells that have undergone a degenerative process because of the age by new cells derived from embryonic stem cell manipulation.

This is a new phase of clinical trial initiated in 2007 (v http://www.fundacion-vision.org.py/docs_v2020/tema227.pdf er). According to Professor Peter Coffey, UCL Institute of Ophthalmology, the tests performed so far in the laboratory have yielded a satisfactory result.

The procedure is to generate in the laboratory of RPE cells qa replacement from stem cells. These new cells are then injected into the affected area (macular region).

already before the scientists themselves have made cell autotransplantation in patients with good prospects, but it is a complicated intervention they manage a few cells (autologous), which limits its use.

aim is to establish a protocol that intervention can be reduced to a 45-minute procedure under local anesthesia.

* Scientists from UCL and Moorfields Hospital, working now to produce cells that can be used clinically with the announced financial support of Pfizer, await first test starting in 2011, once receive authorization medical authorities in the UK.

* Once established steps and protocols is expected that intervention can be reduced to a 45-minute procedure under local anesthesia.

Being a trial still in development, is not expected its application to clinical practice until 2015.

Basic information and guidance. For personalized information consult your ophthalmologist.

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
Eye Center DR. CATOIRA MEDIN